U.S., March 3 -- ClinicalTrials.gov registry received information related to the study (NCT07441837) titled 'Terbium 161 PSMA in Lutetium-177 PSMA Naive Patients' on Feb. 18.
Brief Summary: In this study it is aimed to analyze the efficacy and safety of Tb-161 PSMA I&T in the 7.4 GBq activity in a large patient group of Lu-177 PSMA naive mCRPC patients. 3 cycles of Tb-161 PSMA will be administered with 6 weeks periods. After each cycle a triple bed quantitative single photon emission CT (SPECT)-CT scan from vertex to thigh will be acquired 24 h after every treatment of Tb-161 PSMA. In the first cycle additional time points SPECT-CT acquisitions will be obtained for dosimetric calculations. Details of dosimetry acquisitions will be provided...